Melamix TM
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle |
|---|---|
| 1,4-Benzènediol Quelle : Hydroquinone | 4 % |
Nicht arzneiliche Inhaltsstoffe
Glycérine, Acide glycolique, Dihydrogénophosphate d'aminopropyl, Phénoxyéthanol, Maltodextrine, Acétate de dl-alpha tocophéryle, Extrait de fleur/feuille/tige de Stachys officinalis, Stearyl Alcohol, Caprylyl Glycol, Sodium Metabisulfite, Saponins, EDTA de sodium, Lauryl sulfate de sodium, Extrait de germes de Brassica oleracea italica (Brocoli), Palmitate d'ascorbyle, Aqua, Huile de graine d'Helianthus annuus (Tournesol), Acide ascorbique, bêta-glucane, Sodium Sulphite, Chlorphenesin, Alcool cétylique
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | Non précisée | Non précisée | Non précisée |
In Kanada zugelassene Verwendungen
For the gradual lightening of hyperpigmented skin associated with various skin conditions such as chloasma, melasma, freckles, senile lentigines, and other skin discolourations. Skin bleaching/lightener.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : If you have a family history of, have or have had or are at risk of developing cancer, do not use.To be used only on the advice of a physician. Apply only to small skin surface areas. Discontinue use and consult a physician in case of skin reactions or a blue-black darkening of the skin. In case of accidental ingestion, seek medical assistance or contact a Poison Control Center immediately. Not for use on children under 12 years of age. This product contains glycolic acid, an alpha-hydroxy acid (AHA), which may increase skin's sensitivity to the sun and particularly the possibility of sunburn. Limit sun exposure and apply a sunburn protectant while using this product and for a week afterwards. Use only as directed. Do not apply over sunburn or irritated skin. A mild transient stinging or minor redness may occur in people with sensitive skin. To test for sensitivity, before treatment, apply to an area of approximately 1 cm2 of unbroken skin on the inside of the arm. If no irritation occurs within 24 hours, begin treatment for up to 12 weeks. Discontinue use in case of irritation, rash, excessive inflammatory response or if a gradual blue-black darkening of the skin (exogenous ochronosis) occurs. Minor redness is acceptable, but where there is excessive irritation, a rash or other reaction, further treatment is not advised. Severe itching or reddening may occur, in which case the product should be discontinued and the physician notified immediately. The safety of topical hydroquinone use during pregnancy or for children 12 years old or less has not been established. Note: slight darkening of the product is normal and does not affect its potency. Do not use this product if you have used it or any of its ingredients before and skin sensitivity or irritation has occurred. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product. Close patient supervision is recommended. A bitter taste and anesthetic effect may occur if applied to lips. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure may cause skin re-darkening. Treatment should be limited to relatively small areas of the body at one time.
Originaltext auf Englisch.
Contra-Indications : Do not use this product if you are nursing, pregnant or if you intend to become pregnant within three months of use.For external use only. Do not use near eyes, mucous membranes, or on broken or irritated skin. In case of contact, rinse thoroughly with water. If irritation occurs and/or persists, contact a health care practitioner.
Originaltext auf Englisch.
Known Adverse Reactions : Hypersensitivity (i.e. localized contact dermatitis) may occur; in such case, discontinue use and contact a heath care practitioner. Contains sodium metabisulfite, a sulfite that may cause serious allergic-type reactions including anaphylactic symptoms (e.g. hives, itching), and life threatening or less severe asthmatic episodes in certain susceptible persons.
Originaltext auf Englisch.
Produktdaten
- Andere Namen
- Melamin TM
- Inhaber
- ZO Skin Health Inc.
- NPN oder DIN-HM
- 80038901
- Status
- Lizenz nicht aktiv
- Lizenzdatum
- 21. Januar 2013
- Überarbeitungsdatum
- 10. Juli 2015
- Form
- Crème
- Verabreichungsweg
- Topique
- Art des Antrags
- Non traditionnelle
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80038901
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.